title: Quantitative estimation of tissue prostate specific antigen, deoxyribonucleic acid ploidy and cytological grade in fine needle aspiration biopsies for prognosis of hormonally treated prostatic carcinoma.
abstract: The prognostic value of deoxyribonucleic acid (DNA) flow cytometry, cytological grading and the direct assay of prostate specific antigen (PSA) in the material of fine needle aspirates was studied in 67 consecutive patients with newly detected prostatic carcinoma. All patients were hormonally treated (castration in 27 and luteinizing hormone-releasing hormone agonist or parenteral estrogens in 40). The patients were followed for a minimum of 2 years. PSA was analyzed in the biopsy material by a direct radioimmunoassay and related to the total amount of DNA. In parallel biopsies DNA ploidy using flow cytometry and cytological grade were established. Patients with a geometric mean value of greater than or equal to 0.12 microgram. PSA/microgram. DNA had a progression rate of 7%, compared to 59% for those with less than 0.12 microgram. PSA/microgram. DNA. In Cox multivariate analysis cytology and tissue PSA content were the most important factors in expressing the difference for interval to progression in hormonally treated patients.
authors.affiliation: Department of Urology, Karolinska Institutet, Huddinge University Hospital, Sweden.
authors.forename: R
authors.initials: R
authors.lastname: Stege
authors.forename: B
authors.initials: B
authors.lastname: Tribukait
authors.forename: B
authors.initials: B
authors.lastname: Lundh
authors.forename: K
authors.initials: K
authors.lastname: Carlström
authors.forename: A
authors.initials: A
authors.lastname: Pousette
authors.forename: M
authors.initials: M
authors.lastname: Hasenson
mesh_terms: D000951:Antigens, Neoplasm / Q000032:analysis*; D014408:Biomarkers, Tumor / Q000032:analysis*; D001707:Biopsy, Needle; D002064:Buserelin / Q000031:analogs & derivatives / Q000627:therapeutic use; D004273:DNA, Neoplasm / Q000032:analysis*; D004967:Estrogens / Q000627:therapeutic use; D005500:Follow-Up Studies; D017273:Goserelin; D006801:Humans; D008297:Male; D015999:Multivariate Analysis; D009919:Orchiectomy; D011003:Ploidies; D011379:Prognosis; D017430:Prostate-Specific Antigen; D011471:Prostatic Neoplasms / Q000737:chemistry / Q000235:genetics / Q000473:pathology* / Q000628:therapy
chemical_list: D000951:Antigens, Neoplasm; D014408:Biomarkers, Tumor; D004273:DNA, Neoplasm; D004967:Estrogens; D017273:Goserelin; D017430:Prostate-Specific Antigen; D002064:Buserelin